MUMBAI (Reuters)—The U.S. Department of Justice (DOJ) has subpoenaed India’s largest drugmaker Sun Pharmaceutical Industries Ltd. seeking information about the pricing and marketing of the generic drugs it sells in the U.S., the company said on Saturday.
The DOJ’s antitrust division has also asked Sun Pharma’s U.S. unit for documents related to employee and corporate records and communications with competitors.
The subpoena comes amid a wider probe by U.S. regulators into steep increases in the prices of generic medicines in recent years.
The U.S. Department of Health and Human Services started an investigation last year into generic drug prices after prodding from U.S. Senator Bernie Sanders and Rep. Elijah Cummings (D-Md.).
They specifically cited 100 mg doxycycline hyclate, an antibiotic for which the price doubled in the year through June 2014.
The DOJ’s antitrust division sent subpoenas last year to two generic drugmakers—Endo International Plc. and Mylan—seeking information on their doxycycline products.
Sun Pharma, the world’s fifth-largest maker of generic medicines, is one of several companies selling doxycycline products in the U.S. In a statement issued late on Saturday, it did not disclose the products over which the DOJ had sought information.
Other generic drugmakers, including India’s Dr Reddy’s Laboratories Ltd. and U.S. firm Allergan Plc., also received subpoenas from regulators seeking similar information last year, but they did not disclose the names of the products involved.
